ABSTRACT
OBJECTIVE: To develop and validate the Asthma Severity-Health Search (AS-HScore), predicting severe asthma risk in Italian primary care. According to the current asthma treatment guidelines, the AS-HScore intended to serve as a clinical decision support system (CDSS) for General Practitioners (GPs). METHODS: Using the Health Search Database (HSD), a cohort of 32,917 asthma-diagnosed patients between 2013 and 2021 was identified. The AS-HScore was developed using multivariable Cox regression in a two-part cohort: development and validation. Candidate determinants were estimated and linearly combined to form the score; its predictive accuracy was evaluated in the validation sub-cohort. RESULTS: AS-HScore performance in the validation cohort revealed a 73% area under the curve (i.e. discrimination power) and a 22% pseudo-R2 (explained variation). Calibration slope of 1.07 indicated strong calibration without rejecting the equivalence hypothesis (p = 0.157). Estimating a mean 10% (SD: 6.8%) 1-year risk of severe asthma, GPs might be provided with risk thresholds for patient categorization. CONCLUSION: The AS-HScore emerges as an accurate tool predicting severe asthma risk in the Italian primary care. It therefore shows promising application to enhance asthma care by early identification of severe cases. Implementing a score-based CDSS for Italian GPs holds potential for significantly improving asthma management and patients' outcomes.
ABSTRACT
Recurrent infections of upper and lower respiratory tract have an important clinical and economic impact, which can be reduced through appropriate preventive measures, including the use of immunomodulating agents, such as OM-85, which proved to be effective and safe in both adults and children. Although OM-85 can be useful for the prevention of respiratory tract infections, it is still underused in clinical practice. In order to evaluate the level of awareness of the disease burden of recurrent respiratory infections in adults and children and to assess the level of agreement on the prophylactic and therapeutic approach to the disease, including the use of immunomodulants, a Delphi study was performed. A board of six experts in the field of respiratory infections was appointed to elaborate a series of statements covering four main topics (disease, prevention, OM-85, and future strategies), which were thereafter voted by a panel of 30 experts. Results showed that prevention is unanimously recognized as the most important intervention to reduce disease burden, and the use of immunomodulation to improve the effectiveness of vaccination is gaining increasing favor among clinicians. In this respect, OM-85 is recognized as the most studied immunomodulating agent currently available, whose efficacy and safety make it a valuable tool to optimize the management of recurrent respiratory infections in both adults and children. In particular, the combined use of OM-85 and influenza vaccine was recognized as an effective and safe approach to improve the current prevention strategies in order to reduce the burden of recurrent respiratory infections.
